Traws Pharma receives Nasdaq delisting notice for equity-rule non-compliance

Traws Pharma, Inc.

Nasdaq Staff notified Company on Nov 20, 2024 of non-compliance with $2.5M stockholders' equity requirement (Listing Rule 5550(b)(1)).
Company self-reported equity shortfall and requested Nov 14 hearing solely on equity rule; bid-price compliance was regained on Oct 29.
Awaiting determination from Nasdaq Hearings Panel; delisting remains a risk if plan not accepted.
Previously disclosed bid-price non-compliance resolved by 10 consecutive closing bids above $1.00/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.